ストックスクリーナーアプリを入手
2.24
1.75%
-0.04
アフターアワーズ：
2.24
前日終値:
$2.28
開ける：
$2.27
24時間の取引高:
4.74M
Relative Volume:
3.03
時価総額：
$158.39M
収益：
-
当期純損益:
$-192.96M
株価収益率:
-0.80
EPS:
-2.8
ネットキャッシュフロー:
$-167.04M
1週間 パフォーマンス:
-1.75%
1か月 パフォーマンス:
+30.23%
6か月 パフォーマンス:
-10.76%
1年 パフォーマンス:
+7.69%
1日の値動き範囲:
$2.24
$2.36
1週間の範囲:
$2.205
$2.5391
52週間の値動き範囲:
$1.67
$11.48
Ventyx Biosciences Inc Stock (VTYX) Company Profile
名前
Ventyx Biosciences Inc
セクター
電話
(858) 945-2393
住所
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
VTYX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
2.24 | 158.39M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-12 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-03-12 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-11-07 | ダウングレード | Stifel | Buy → Hold |
| 2023-11-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-03-21 | 開始されました | Wells Fargo | Overweight |
| 2022-12-19 | 開始されました | Goldman | Buy |
| 2022-11-17 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-07 | 開始されました | Stifel | Buy |
| 2022-09-01 | 開始されました | H.C. Wainwright | Buy |
| 2022-05-09 | 開始されました | Credit Suisse | Outperform |
| 2022-03-31 | 開始されました | Canaccord Genuity | Buy |
| 2022-02-01 | 開始されました | Oppenheimer | Outperform |
| 2021-11-15 | 開始されました | Jefferies | Buy |
| 2021-11-15 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Ventyx Biosciences Inc (VTYX) 最新ニュース
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider John Nuss Sells 13,161 Shares - MarketBeat
Ventyx Biosciences' chief scientific officer sells $29,682 in stock - Investing.com
Ventyx Biosciences' chief scientific officer sells $29,682 in stock By Investing.com - Investing.com UK
Insiders Enjoy US$190k Return After Buying Ventyx Biosciences Stock - Simply Wall St
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k - Yahoo Finance
VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Cryopyrin-associated Periodic Syndromes Market on Track for Major Expansion by 2034, According to DelveInsight | Amgen, Biovitrum, Novartis, Ventyx Biosciences - The Globe and Mail
Neurogene and Ventyx Biosciences rises after insider buying by executives - MSN
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Bought by Vestal Point Capital LP - MarketBeat
Sio Capital Management LLC Raises Stock Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - MarketBeat
Hedge Fund and Insider Trading News: Bill Ackman, Paul Tudor Jones, Whitney Tilson, Steven Cohen, Scott Bessent, Millennium Management, Paloma Partners, Ventyx Biosciences Inc (VTYX), Vistra Corp (VST), and More - Insider Monkey
Ventyx Biosciences Inc (NASDAQ: VTYX) Jumps 11.35%, Turning Investors Away - Stocks Register
Ventyx Biosciences CEO Mohan Raju buys $959,889 in stock By Investing.com - Investing.com Australia
Ventyx Biosciences CEO Mohan Raju buys $959,889 in stock - Investing.com
Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) Price Target at $10.00 - MarketBeat
Thinking about buying stock in Solid Power, Crowdstrike Holdings - GuruFocus.com
Ventyx Biosciences stock hits 52-week low at $1.78 amid market shifts - Investing.com Australia
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully - Simply Wall St
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress - Yahoo Finance
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - The Manila Times
Ventyx Biosciences (NASDAQ:VTYX) Earns "Neutral" Rating from HC Wainwright - MarketBeat
Ventyx Biosciences’ (VTYX) “Outperform” Rating Reiterated at Oppenheimer - Defense World
Ventyx Biosciences (NASDAQ:VTYX) Given "Outperform" Rating at Oppenheimer - MarketBeat
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress - The Manila Times
Vanguard Group Inc's Strategic Acquisition in Ventyx Biosciences Inc - GuruFocus.com
Ventyx Biosciences: Ready To Escape "The Crash Cycle" (NASDAQ:VTYX) - Seeking Alpha
Thinking about buying stock in QuickLogic, Ventyx Biosciences, D - GuruFocus.com
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Markets Insider
Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $8.29 - MarketBeat
HC Wainwright Cuts Earnings Estimates for Ventyx Biosciences - MarketBeat
Ventyx Biosciences maintains Neutral rating from H.C. Wainwright - Investing.com
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 in Ulcerative Colitis at UEG Week 2024 - Marketscreener.com
Ventyx Biosciences maintains Neutral rating from H.C. Wainwright By Investing.com - Investing.com UK
Ventyx Biosciences Presents New 52-Week Results from the - GlobeNewswire
Ventyx Biosciences (NASDAQ:VTYX) Given "Neutral" Rating at HC Wainwright - MarketBeat
Ventyx reports positive Phase 2 ulcerative colitis trial data - Investing.com
Ventyx reports positive Phase 2 ulcerative colitis trial data By Investing.com - Investing.com Canada
VTYX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Ventyx Biosciences Inc (VTYX) stock analysis: A comprehensive overview - US Post News
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024 - The Manila Times
Did Ventyx Biosciences Inc (VTYX) perform well in the last session? - US Post News
Ventyx Biosciences Inc (VTYX) 財務データ
収益
当期純利益
現金流量
EPS
Ventyx Biosciences Inc (VTYX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 19 '24 |
Sale |
2.26 |
13,161 |
29,682 |
485,701 |
| Mohan Raju | CEO AND PRESIDENT |
Dec 17 '24 |
Option Exercise |
0.00 |
116,668 |
0 |
2,291,696 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):